Why the push for policies between universities and the pharma industry?

Medical: A new study has exposed the inadequacy of current conflict of interest policies at Australian universities, leaving medical students susceptible to the sway of commercial interests. The comprehensive review, which scrutinised conflict of interest policies across multiple Australian medical schools, has shed light on the gaps and inconsistencies that may pose as a threat to the integrity of medical education.

The research was prompted by the Australian Medical Students’ Association (AMSA), who reached out to Professor Barbara Mintzes, senior author of the study from the University of Sydney’s Charles Perkins Centre, Faculty of Medicine and Health. AMSA revised its own policy, calling for stronger action to prevent conflicts of interest in medical schools and practice.

The study analysed conflict of interest policies from 21 Australian medical school and host university websites. The findings showed only two policies specifically tailored to medical schools out of the 155 examined. The remaining 153 policies were broad, university-wide guidelines that failed to address the unique challenges that may be posed by commercial influence on medical practice.

Key medicine-specific issues were absent from the policies, including protocols for student interaction with sales representatives, regulation of industry funding for on-site sponsored education, and guidelines for the use of free medicine samples. Such oversights, the researchers argue, have far-reaching implications for medical students’ education, clinical decision-making, and patient care.

“Financial relationships with industry can detrimentally influence medical education and clinical decision-making, which include inappropriate prescribing and overdiagnosis,” warned Professor Barbara Mintzes, senior author of the study from the University of Sydney’s Charles Perkins Centre, Faculty of Medicine and Health.

This study has ignited a debate, with opinions divided on the role of the pharmaceutical industry in medical education. While some argue that collaboration is essential for advancements in research and innovation, critics emphasise that patient wellbeing and unbiased medical education should never be compromised.

Professor Mintzes advocated for the development of comprehensive national guidelines that address the complex relationship between medical practice, education, and industry. While some improvements have been made regarding consulting roles and relationships, the researchers stress the importance of school-specific conflict of interest policies. International research from the United States supports this claim, demonstrating that doctors who attended medical schools with stronger conflict of interest policies exhibited more appropriate prescribing practices compared to those from schools with weaker policies.

Dr Travis Lines, a lead author on AMSA’s Pharmaceutical sponsorship and relationship with industry policy, expressed concern about the risk to Australia’s high standards in medical education, stating, “Failing to regulate conflicts of interest stops us from providing the best care to our patients.”

The onus now falls on medical schools, regulatory bodies, and policymakers to enact stricter regulations and ensure transparency in the relationships between medical professionals, students, and the pharmaceutical industry. Calls for a centralised conflict of interest policy, applicable across all Australian medical schools, may promote consistency and accountability.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.